Medical technology companies are, by their very nature, engines of innovation. From the early-stage startup refining a wearable glucose monitor to the established manufacturer optimizing its surgical robotics platform, MedTech organizations invest enormous resources in solving problems that have never been solved before. What many of those organizations don’t fully appreciate is that a substantial portion of that investment may qualify for one of the most powerful incentives in the U.S. tax code: the federal Research and Development (R&D) Tax Credit under Internal Revenue Code Section 41.
For decision-makers navigating tight development budgets, and for the tax professionals advising them, understanding how this credit applies to MedTech is no longer optional. It’s a strategic imperative.
What the Credit Is (and Isn’t)
The R&D Tax Credit provides a dollar-for-dollar reduction in federal income tax liability for companies engaged in qualified research activities. Despite the name, the credit is not reserved for Nobel Prize-worthy breakthroughs or white-coat laboratory science. The IRS defines eligibility around a structured process of experimentation, not the outcome of it.
Critically, a project does not need to succeed to qualify. The credit rewards the attempt to eliminate technical uncertainty through a methodical process. In an industry where iteration and redesign are standard operating procedure, this distinction is significant.
The Four-Part Test: Applied to MedTech Reality
To qualify under IRC §41, research activities must satisfy four criteria. Understanding how these map to MedTech operations is essential for both identifying eligible work and defending claims under audit.
1. Business Purpose. The research must be aimed at developing a new or improved business component: a product, process, software, technique, formula, or invention. In MedTech, this encompasses device development, embedded firmware, manufacturing process improvement, and diagnostic software, among many other activities.
2. Elimination of Technical Uncertainty. The company must be attempting to resolve uncertainty about the capability, method, or appropriate design of the business component. Designing a novel implant material, developing a new signal-processing algorithm for a diagnostic device, or improving yield in a sterile manufacturing process all involve genuine technical uncertainty.
3. Process of Experimentation. The company must pursue a systematic process to evaluate alternatives: modeling, simulation, prototyping, testing, and iterating. The structured nature of MedTech development, governed by design controls and validation protocols, frequently aligns well with this requirement.
4. Technological in Nature. The work must rely on principles of engineering, computer science, biological science, or physical science. Given that MedTech inherently sits at the intersection of these disciplines, this test is generally straightforward to satisfy.
What Qualifies in the MedTech Context
The range of qualifying activities in medical technology is broader than most organizations realize. Common examples include:
- Product development and design engineering: Creating new devices or meaningfully improving existing ones, including both hardware and software components
- Prototyping and validation testing: Building and evaluating prototypes against regulatory and performance standards; this includes FDA-required testing that involves resolving technical uncertainty (not merely confirming known performance)
- Embedded software and firmware development: Designing algorithms, control logic, or user interface software for devices
- Manufacturing process development: Engineering new processes or improving existing ones to enhance consistency, yield, or safety
- Materials science and biocompatibility research: Evaluating new materials for structural, chemical, or biological performance in clinical environments
- Regulatory-driven redesign: Engineering changes required by evolving FDA guidance that necessitate resolving new technical uncertainties
One important nuance for tax professionals: not all FDA-related testing automatically qualifies. Only activities that involve resolving genuine technical uncertainty are eligible. Routine testing of known processes or adaptations that don’t require experimentation typically fall outside the credit’s scope.
Qualified Research Expenses: What Can Be Claimed
Once qualifying activities are identified, the credit is calculated based on Qualified Research Expenses (QREs), which include:
- Wages paid to employees performing, supervising, or supporting qualified research. If at least 80% of an employee’s time is devoted to qualifying activities, 100% of their wages may be included.
- Supplies used or consumed in the research process: prototype materials, reagents, and other tangible items directly consumed in experimentation.
- Contract research expenses: 65% of amounts paid to third-party contractors performing qualified research on the company’s behalf, provided the company retains substantial rights to the research and bears the economic risk.
The credit itself is generally calculated at 20% of QREs above a computed base amount under the regular credit method, or at 14% of QREs exceeding 50% of the average QREs for the prior three years under the Alternative Simplified Credit (ASC) method. Most companies benefit from calculating under both methods and selecting the more favorable result.
The Current Legislative Landscape: A Significant Shift
For companies and advisors engaged in tax planning right now, the legislative environment warrants close attention.
The One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, restored and permanently reinstated immediate expensing of domestic research expenses under new IRC §174A. This reverses the amortization requirement that had been in effect for tax years 2022 through 2024, during which domestic R&D costs were required to be capitalized and amortized over five years. For MedTech companies with significant domestic R&D spend, this is a meaningful cash-flow restoration.
Two transition rules apply to previously amortized expenses. Companies may elect to deduct remaining unamortized domestic R&D costs entirely in 2025, or spread them over 2025 and 2026. Eligible small businesses may also elect to apply §174A retroactively by amending their 2022–2024 returns.
These changes are separate from the §41 credit, but they interact directly with overall tax strategy. Companies should be modeling both levers simultaneously.
Additionally, the OBBBA raised the gross receipts threshold for the Qualified Small Business (QSB) payroll tax credit election from $5 million to $31 million, meaningfully expanding access for growth-stage MedTech companies. Qualifying businesses can now apply up to $500,000 of the federal R&D credit against payroll tax liability, providing real cash value even when income tax liability is limited.
At the state level, 37 states currently offer their own R&D credit programs, with California and Texas both making notable improvements to their respective programs in 2025. For MedTech companies with operations in multiple states, a comprehensive state-level analysis is often worth the effort.
Documentation: The Foundation of a Defensible Claim
The R&D Tax Credit is one of the more heavily scrutinized items in a corporate tax return. A well-prepared claim requires more than identifying qualifying activities, it requires evidence that those activities meet the four-part test and that the expenses are properly substantiated.
Best practices include structured interviews with engineering, R&D, and manufacturing personnel to capture activity-level detail; project-level expense allocation tied to QRE categories; contemporaneous time-tracking for employees performing qualified services; and records demonstrating the process of experimentation: iteration histories, design reviews, test protocols, and failure analyses.
For MedTech companies, where hardware, software, materials science, and manufacturing engineering frequently overlap within a single program, mapping expenses to qualified activities requires both technical knowledge and tax expertise. Generic documentation approaches fall short. The most defensible claims are built on narratives that explain, specifically, how each component of the four-part test is satisfied for each business component under review.
The Strategic Case for Acting Now
Given the scale of R&D investment in MedTech, and the compounding effect of unclaimed credits across open tax years, the cost of inaction is material. The federal R&D Tax Credit can be claimed retroactively on amended returns for open tax years, typically three years, though longer if losses were incurred.
For MedTech decision-makers, the message is straightforward: the work your teams are doing every day to solve hard engineering problems and bring better diagnostics, therapeutics, and devices to market is exactly the kind of innovation this credit was designed to reward. The question is whether your organization has the processes and partnerships in place to capture that value.
For tax professionals serving MedTech clients, the combination of newly restored §174A expensing, an expanded QSB payroll credit threshold, and a pipeline of potentially unclaimed prior-year credits makes this one of the most consequential areas of tax planning for the industry right now.
The credit exists. The activities qualify. The documentation discipline is what determines whether the value is captured, or left on the table.
